Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 248

1.

Immune monitoring in allogeneic hematopoietic stem cell transplant recipients: a survey from the EBMT-CTIWP.

Greco R, Ciceri F, Noviello M, Bondanza A, Vago L, Oliveira G, Peccatori J, Cieri N, Ruggeri A, Koehl U, Fleischhauer K, Rocha V, Dazzi F, van der Werf SM, Eikema DJ, Terwel SR, Kuball J, Toubert A, Chabannon C, Bonini C; EBMT Cellular Therapy and Immunobiology Working Party (CTIWP).

Bone Marrow Transplant. 2018 Apr 17. doi: 10.1038/s41409-018-0167-8. [Epub ahead of print] No abstract available.

PMID:
29666449
2.

Hematopoietic stem cell transplantation in its 60s: A platform for cellular therapies.

Chabannon C, Kuball J, Bondanza A, Dazzi F, Pedrazzoli P, Toubert A, Ruggeri A, Fleischhauer K, Bonini C.

Sci Transl Med. 2018 Apr 11;10(436). pii: eaap9630. doi: 10.1126/scitranslmed.aap9630. Review.

PMID:
29643233
3.

Considerations pertaining to cell collection and administration of industry-manufactured autologous CAR-T cells, in relation to French healthcare organization and regulations.

Chabannon C, Larghero J.

Curr Res Transl Med. 2018 Apr 3. pii: S2452-3186(18)30018-7. doi: 10.1016/j.retram.2018.03.002. [Epub ahead of print]

PMID:
29625832
4.

Cost-effectiveness analysis of haploidentical vs matched unrelated allogeneic hematopoietic stem cells transplantation in patients older than 55 years.

Debals-Gonthier M, Siani C, Faucher C, Touzani R, Lemarié-Basset C, Chabannon C, Furst S, Devillier R, Harbi S, Castagna L, Caymaris L, Blaise D, Le Corroller Soriano AG.

Bone Marrow Transplant. 2018 Mar 9. doi: 10.1038/s41409-018-0133-5. [Epub ahead of print]

PMID:
29523885
5.

HLA-Matched Sibling versus Unrelated versus Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patients Aged Over 60 Years with Acute Myeloid Leukemia: A Single-Center Donor Comparison.

Devillier R, Legrand F, Rey J, Castagna L, Fürst S, Granata A, Charbonnier A, Harbi S, d'Incan E, Pagliardini T, Faucher C, Lemarie C, Saillard C, Calmels B, Mohty B, Maisano V, Weiller PJ, Chabannon C, Vey N, Blaise D.

Biol Blood Marrow Transplant. 2018 Feb 12. pii: S1083-8791(18)30080-6. doi: 10.1016/j.bbmt.2018.02.002. [Epub ahead of print]

PMID:
29448057
6.

Corrigendum: Disease status is a more reliable predictive factor than histology in lymphoma patients after reduced-intensity conditioning regimen and allo-SCT.

Castagna L, Boubdallah R, Furst S, Coso D, El Cheikh J, Faucher C, Crocchiolo R, Granata A, Chabannon C, Lemarié C, Calmels B, Boher JM, Mohty M, Blaise D.

Bone Marrow Transplant. 2018 Feb;53(2):234. doi: 10.1038/bmt.2018.1.

PMID:
29410535
7.

Secondary malignancies after high-dose chemotherapy in germ cell tumor patients: a 34-year retrospective study of the European Society for Blood and Marrow Transplantation (EBMT).

Necchi A, Lo Vullo S, Secondino S, Rosti G, Badoglio M, Giannatempo P, Raggi D, Lanza F, Chabannon C, Bonini C, Mariani L, Pedrazzoli P; European Society for Blood and Marrow Transplantation, Cellular Therapy & Immunobiology Working Party – Solid Tumor sub-committee.

Bone Marrow Transplant. 2018 Jan 24. doi: 10.1038/s41409-017-0079-z. [Epub ahead of print]

PMID:
29367713
8.

Handling, processing and disposal of stem cell products in Europe: A survey by the cellular therapy and immunobiology working party of the European Society for Blood and Marrow Transplantation.

Holbro A, Baldomero H, Lanza F, Chabannon C, Snowden JA, Buser A, Infanti L, Worel N, Sureda A, Badoglio M, Passweg J, Bonini C; Cellular Therapy & Immunobiology Working Party of the European Society for Blood & Marrow Transplantation (EBMT) and the Joint Accreditation Committee International Society for Cellular Therapy & EBMT (JACIE).

Cytotherapy. 2018 Mar;20(3):453-460. doi: 10.1016/j.jcyt.2017.12.005. Epub 2018 Jan 17.

PMID:
29352666
9.

From clinical proof-of-concept to commercialization of CAR T cells.

Calmels B, Mfarrej B, Chabannon C.

Drug Discov Today. 2018 Apr;23(4):758-762. doi: 10.1016/j.drudis.2018.01.024. Epub 2018 Jan 6.

PMID:
29317339
10.

Early prognostic factors in septic shock cancer patients: a prospective study with a proteomic approach.

Mokart D, Saillard C, Zemmour C, Bisbal M, Sannini A, Chow-Chine L, Brun JP, Faucher M, Boher JM, Toiron Y, Chabannon C, Borg JP, Gonçalves A, Camoin L.

Acta Anaesthesiol Scand. 2018 Apr;62(4):493-503. doi: 10.1111/aas.13060. Epub 2018 Jan 7.

PMID:
29315472
11.

Tandem autologous-haploidentical transplantation is a feasible and effective program for refractory Hodgkin lymphoma.

Mariotti J, Bramanti S, Devillier R, Furst S, El Cheikh J, Sarina B, Granata A, Faucher C, Harbi S, Morabito L, Weiller PJ, Chabannon C, Mokart J, Mineri R, Carlo-Stella C, Santoro A, Blaise D, Castagna L.

Bone Marrow Transplant. 2018 Mar;53(3):366-370. doi: 10.1038/s41409-017-0032-1. Epub 2017 Dec 21. No abstract available.

PMID:
29269800
12.

Plerixafor in poor mobilizers with non-Hodgkin's lymphoma: a multi-center time-motion analysis.

Mohty M, Azar N, Chabannon C, Le Gouill S, Karlin L, Farina L, Milkovich G, Ostermann H, Glaß B, Noppeney R, Kron F, Kron A, Hübel K.

Bone Marrow Transplant. 2018 Mar;53(3):246-254. doi: 10.1038/s41409-017-0033-0. Epub 2017 Dec 18.

PMID:
29255168
13.

Killer Cell Immunoglobulin-Like Receptor-Ligand Mismatch in Donor versus Recipient Direction Provides Better Graft-versus-Tumor Effect in Patients with Hematologic Malignancies Undergoing Allogeneic T Cell-Replete Haploidentical Transplantation Followed by Post-Transplant Cyclophosphamide.

Wanquet A, Bramanti S, Harbi S, Fürst S, Legrand F, Faucher C, Granata A, Calmels B, Lemarie C, Picard C, Chabannon C, Weiller PJ, Castagna L, Blaise D, Devillier R.

Biol Blood Marrow Transplant. 2018 Mar;24(3):549-554. doi: 10.1016/j.bbmt.2017.11.042. Epub 2017 Dec 13.

PMID:
29247781
14.

Jon van Rood (1926-2017).

Mueller C, Bonini C, Foeken L, Chabannon C, Bondanza A, Fleischhauer K, Velardi A, Kröger N, Kuball J, Mohty M.

Bone Marrow Transplant. 2017 Dec;52(12):1587. doi: 10.1038/bmt.2017.242. No abstract available.

PMID:
29209062
15.

CAR-T cells: the narrow path between hope and bankruptcy?

Chabannon C, Kuball J, Mcgrath E, Bader P, Dufour C, Lankester A, Basak GW, Montoto S, Nagler A, Snowden JA, Styczynski J, Duarte RF, Kröger N, Mohty M.

Bone Marrow Transplant. 2017 Dec;52(12):1588-1589. doi: 10.1038/bmt.2017.241. No abstract available.

PMID:
29209061
16.

T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Hodgkin Lymphoma Relapsed after Autologous Transplantation: Reduced Incidence of Relapse and of Chronic Graft-versus-Host Disease Compared with HLA-Identical Related Donors.

Mariotti J, Devillier R, Bramanti S, Sarina B, Furst S, Granata A, Faucher C, Harbi S, Morabito L, Chabannon C, Carlo-Stella C, Bouabdallah R, Santoro A, Blaise D, Castagna L.

Biol Blood Marrow Transplant. 2018 Mar;24(3):627-632. doi: 10.1016/j.bbmt.2017.11.030. Epub 2017 Nov 29.

PMID:
29197681
17.

[Prerequisite for hematopoietic cellular therapy programs to set up chimeric antigen receptor T-cell therapy (CAR T-cells): Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Yakoub-Agha I, Ferrand C, Chalandon Y, Ballot C, Castilla Llorente C, Deschamps M, Gauthier J, Labalette M, Larghero J, Maheux C, Moreau AS, Varlet P, Pétillon MO, Pinturaud M, Rubio MT, Chabannon C.

Bull Cancer. 2017 Dec;104(12S):S43-S58. doi: 10.1016/j.bulcan.2017.10.017. Epub 2017 Nov 23. French.

PMID:
29174320
18.

[Non eligibility criteria for hematopoietic stem cell donors: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Boiron JM, Garban F, Audat F, Ader V, Andreu H, Aubrège-Bouvier C, Borel C, Huynh P, Nacimento F, Yakoub-Agha I, Chabannon C.

Bull Cancer. 2017 Dec;104(12S):S76-S83. doi: 10.1016/j.bulcan.2017.06.022. Epub 2017 Nov 22. French.

PMID:
29173975
19.

Pre-clinical assessment of the Lovo device for dimethyl sulfoxide removal and cell concentration in thawed hematopoietic progenitor cell grafts.

Mfarrej B, Bouchet G, Couquiaud J, Regimbaud L, Binninger S, Mercier M, Lemarié C, Houzé P, Chabannon C, Calmels B.

Cytotherapy. 2017 Dec;19(12):1501-1508. doi: 10.1016/j.jcyt.2017.09.001. Epub 2017 Oct 14.

20.

[The biological complexity of Polycomb group proteins: the case of EZH2].

Koubi M, Chabannon C, Duprez E.

Med Sci (Paris). 2017 May;33(5):499-505. doi: 10.1051/medsci/20173305013. Epub 2017 Jun 14. Review. French.

PMID:
28612725
21.

The choice of in-hospital or home administration for plerixafor injection to poor mobilizers has no adverse consequence on subsequent hematopoietic stem cell harvest.

Chabannon C, Bijou F, Grouin JM, Drillat P, Milpied N, Mohty M.

Bone Marrow Transplant. 2017 Aug;52(8):1212-1214. doi: 10.1038/bmt.2017.103. Epub 2017 Jun 5. No abstract available.

PMID:
28581475
22.

Addition of plerixafor to G-CSF is useful to achieve efficient collection even in very poor mobilizers: hope for patients with diminished hematopoietic function.

Mohty M, Drillat P, Grouin JM, Bijou F, Milpied N, Chabannon C.

Bone Marrow Transplant. 2017 Jul;52(7):1049-1050. doi: 10.1038/bmt.2017.80. Epub 2017 May 22. No abstract available.

PMID:
28530669
23.

Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma.

Castagna L, Bramanti S, Devillier R, Sarina B, Crocchiolo R, Furst S, El-Cheikh J, Granata A, Faucher C, Harbi S, Morabito L, Mariotti J, Puvinathan S, Weiller PJ, Chabannon C, Mokart D, Carlo-Stella C, Bouabdallah R, Santoro A, Blaise D.

Bone Marrow Transplant. 2017 May;52(5):797. doi: 10.1038/bmt.2017.26. No abstract available.

PMID:
28465624
24.

JACIE accreditation for blood and marrow transplantation: past, present and future directions of an international model for healthcare quality improvement.

Snowden JA, McGrath E, Duarte RF, Saccardi R, Orchard K, Worel N, Kuball J, Chabannon C, Mohty M.

Bone Marrow Transplant. 2017 Oct;52(10):1367-1371. doi: 10.1038/bmt.2017.54. Epub 2017 Mar 27.

25.

[Impact of Her2 and BRCA1/2 status in high-dose chemotherapy and autologous stem cells transplantation in the treatment of breast cancer: The Institut Paoli Calmettes' experience].

Boudin L, Chabannon C, Sfumato P, Sabatier R, Bertucci F, Tarpin C, Provansal M, Houvenaeghel G, Lambaudie E, Tallet A, Resbeut M, Charafe-Jauffret E, Calmels B, Lemarie C, Boher JM, Extra JM, Viens P, Gonçalves A.

Bull Cancer. 2017 Apr;104(4):332-343. doi: 10.1016/j.bulcan.2016.12.007. Epub 2017 Feb 16. French.

PMID:
28214007
26.

Impact of CD34-positive cell dose on outcome after peripheral blood stem cell allogeneic transplantation prepared with ATG-based reduced intensity conditioning regimen.

Collignon A, Calmels B, Harbi S, Fürst S, Granata A, Faucher C, Lemarie C, Weiller PJ, Chabannon C, Blaise D, Devillier R.

Am J Hematol. 2017 Apr;92(4):E57-E59. doi: 10.1002/ajh.24661. Epub 2017 Feb 24. No abstract available.

27.

Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation.

Boudin L, Gonçalves A, Sabatier R, Moretta J, Sfumato P, Asseeva P, Livon D, Bertucci F, Extra JM, Tarpin C, Houvenaeghel G, Lambaudie E, Tallet A, Resbeut M, Sobol H, Charafe-Jauffret E, Calmels B, Lemarie C, Boher JM, Viens P, Eisinger F, Chabannon C.

Bone Marrow Transplant. 2017 Mar;52(3):498. doi: 10.1038/bmt.2016.291. Epub 2017 Jan 16. No abstract available.

PMID:
28092355
28.

Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma.

Castagna L, Bramanti S, Devillier R, Sarina B, Crocchiolo R, Furst S, El-Cheikh J, Granata A, Faucher C, Harbi S, Morabito L, Mariotti J, Puvinathan S, Weiller PJ, Chabannon C, Mokart D, Carlo-Stella C, Bouabdallah R, Santoro A, Blaise D.

Bone Marrow Transplant. 2017 May;52(5):683-688. doi: 10.1038/bmt.2016.348. Epub 2017 Jan 16. Erratum in: Bone Marrow Transplant. 2017 May;52(5):797.

PMID:
28092347
29.

Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML.

Legrand F, Le Floch AC, Granata A, Fürst S, Faucher C, Lemarie C, Harbi S, Bramanti S, Calmels B, El-Cheikh J, Chabannon C, Weiller PJ, Vey N, Castagna L, Blaise D, Devillier R.

Bone Marrow Transplant. 2017 Apr;52(4):620-621. doi: 10.1038/bmt.2016.326. Epub 2016 Dec 12. No abstract available.

PMID:
27941765
30.

Manufacturing Natural Killer Cells as Medicinal Products.

Chabannon C, Mfarrej B, Guia S, Ugolini S, Devillier R, Blaise D, Vivier E, Calmels B.

Front Immunol. 2016 Nov 15;7:504. eCollection 2016. Review.

31.

Prognostic impact of hormone receptor- and HER2-defined subtypes in inflammatory breast cancer treated with high-dose chemotherapy: a retrospective study.

Boudin L, Gonçalves A, Sfumato P, Sabatier R, Bertucci F, Tarpin C, Provansal M, Houvenaeghel G, Lambaudie E, Tallet A, Resbeut M, Charafe-Jauffret E, Calmels B, Lemarie C, Boher JM, Extra JM, Viens P, Chabannon C.

J Cancer. 2016 Oct 23;7(14):2077-2084. eCollection 2016.

32.

Outcomes of Hodgkin lymphoma patients who relapse after allogeneic stem cell transplantation.

Castagna L, Sarina B, Crocchiolo R, Bramanti S, Furst S, Devillier R, Coso D, Bouabdallah R, Mokart D, Morabito L, Harbi S, Giordano L, Rimondo A, Jean Weiller P, Carlo-Stella C, Santoro A, Chabannon C, Blaise D.

Bone Marrow Transplant. 2016 Dec;51(12):1644-1646. doi: 10.1038/bmt.2016.257. Epub 2016 Oct 17. No abstract available.

PMID:
27748737
33.

Corrigendum to "Immunohistochemical subtypes predict survival in metastatic breast cancer receiving high-dose chemotherapy with autologous haematopoietic stem cell transplantation" [Eur J Cancer 57 (April 2016) 118-126].

Boudin L, Chabannon C, Sfumato P, Sabatier R, Bertucci F, Tarpin C, Provansal M, Houvenaeghel G, Lambaudie E, Tallet A, Resbeut M, Charafe-Jauffret E, Calmels B, Lemarie C, Boher JM, Extra JM, Viens P, Gonçalves A.

Eur J Cancer. 2016 Nov;67:223. doi: 10.1016/j.ejca.2016.09.002. Epub 2016 Sep 24. No abstract available.

PMID:
27680408
34.

The calcineurin inhibitor and the intensity of the conditioning regimen may affect the occurrence of polyomavirus-associated hemorrhagic cystitis after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide.

Rimondo A, Crocchiolo R, El-Cheikh J, Bramanti S, Granata A, Furst S, Sarina B, Morabito L, Devillier R, Harbi S, Mohty B, Mineri R, Faucher C, Chabannon C, Santoro A, Blaise D, Castagna L.

Bone Marrow Transplant. 2017 Jan;52(1):135-137. doi: 10.1038/bmt.2016.193. Epub 2016 Jul 18. No abstract available.

PMID:
27427919
35.

Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy.

Moschoi R, Imbert V, Nebout M, Chiche J, Mary D, Prebet T, Saland E, Castellano R, Pouyet L, Collette Y, Vey N, Chabannon C, Recher C, Sarry JE, Alcor D, Peyron JF, Griessinger E.

Blood. 2016 Jul 14;128(2):253-64. doi: 10.1182/blood-2015-07-655860. Epub 2016 Jun 2.

36.

Characterization of leukemias with ETV6-ABL1 fusion.

Zaliova M, Moorman AV, Cazzaniga G, Stanulla M, Harvey RC, Roberts KG, Heatley SL, Loh ML, Konopleva M, Chen IM, Zimmermannova O, Schwab C, Smith O, Mozziconacci MJ, Chabannon C, Kim M, Frederik Falkenburg JH, Norton A, Marshall K, Haas OA, Starkova J, Stuchly J, Hunger SP, White D, Mullighan CG, Willman CL, Stary J, Trka J, Zuna J.

Haematologica. 2016 Sep;101(9):1082-93. doi: 10.3324/haematol.2016.144345. Epub 2016 May 26.

37.

Low incidence of chronic GVHD after HLA-haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide in older patients.

Devillier R, Granata A, Fürst S, Harbi S, Faucher C, Weiller PJ, Chabannon C, Castagna L, Blaise D.

Br J Haematol. 2017 Jan;176(1):132-135. doi: 10.1111/bjh.13923. Epub 2016 Apr 12. No abstract available.

PMID:
27073182
38.

Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation.

Boudin L, Gonçalves A, Sabatier R, Moretta J, Sfumato P, Asseeva P, Livon D, Bertucci F, Extra JM, Tarpin C, Houvenaeghel G, Lambaudie E, Tallet A, Resbeut M, Sobol H, Charafe-Jauffret E, Calmels B, Lemarie C, Boher JM, Viens P, Eisinger F, Chabannon C.

Bone Marrow Transplant. 2016 Aug;51(8):1082-6. doi: 10.1038/bmt.2016.82. Epub 2016 Apr 4. Erratum in: Bone Marrow Transplant. 2017 Mar;52(3):498.

PMID:
27042835
39.

The patient's CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide.

Crocchiolo R, Castagna L, Furst S, Devillier R, Sarina B, Bramanti S, El-Cheikh J, Granata A, Harbi S, Morabito L, Faucher C, Rimondo A, Girardi D, Mohty B, Calmels B, Carlo-Stella C, Chabannon C, Bouabdallah R, Santoro A, Vey N, Weiller PJ, Blaise D.

Bone Marrow Transplant. 2016 Aug;51(8):1134-6. doi: 10.1038/bmt.2016.69. Epub 2016 Mar 21. No abstract available.

PMID:
26999460
40.

Frequency and Dynamics of Leukemia-Initiating Cells during Short-term Ex Vivo Culture Informs Outcomes in Acute Myeloid Leukemia Patients.

Griessinger E, Anjos-Afonso F, Vargaftig J, Taussig DC, Lassailly F, Prebet T, Imbert V, Nebout M, Vey N, Chabannon C, Filby A, Bollet-Quivogne F, Gribben JG, Peyron JF, Bonnet D.

Cancer Res. 2016 Apr 15;76(8):2082-6. doi: 10.1158/0008-5472.CAN-15-2063. Epub 2016 Mar 9.

41.
42.

Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamide.

Castagna L, Bramanti S, Furst S, Giordano L, Sarina B, Crocchiolo R, El-Cheikh J, Granata A, Morabito L, Mauro E, Faucher C, Mohty B, Harbi S, Devillier R, Chabannon C, Carlo-Stella C, Santoro A, Blaise D.

Bone Marrow Transplant. 2016 Mar;51(3):470. doi: 10.1038/bmt.2015.327. No abstract available.

PMID:
26931485
43.

Immunohistochemical subtypes predict survival in metastatic breast cancer receiving high-dose chemotherapy with autologous haematopoietic stem cell transplantation.

Boudin L, Chabannon C, Sfumato P, Sabatier R, Bertucci F, Tarpin C, Provansal M, Houvenaeghel G, Lambaudie E, Tallet A, Resbeut M, Charafe-Jauffret E, Calmels B, Lemarie C, Boher JM, Extra JM, Viens P, Gonçalves A.

Eur J Cancer. 2016 Apr;57:118-26. doi: 10.1016/j.ejca.2016.01.005. Epub 2016 Feb 23. Erratum in: Eur J Cancer. 2016 Nov;67:223.

PMID:
26918737
44.

The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m(2) intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myelodysplastic syndrome or acute leukemia.

Wanquet A, Crocchiolo R, Furst S, Granata A, Faucher C, Devillier R, Harbi S, Lemarie C, Calmels B, Vey N, Weiller PJ, Chabannon C, Castagna L, Blaise D, El-Cheikh J.

Leuk Lymphoma. 2016 Oct;57(10):2315-20. doi: 10.3109/10428194.2016.1146948. Epub 2016 Feb 17.

PMID:
26885686
45.

Banking or Bankrupting: Strategies for Sustaining the Economic Future of Public Cord Blood Banks.

Magalon J, Maiers M, Kurtzberg J, Navarrete C, Rubinstein P, Brown C, Schramm C, Larghero J, Katsahian S, Chabannon C, Picard C, Platz A, Schmidt A, Katz G.

PLoS One. 2015 Dec 1;10(12):e0143440. doi: 10.1371/journal.pone.0143440. eCollection 2015.

46.

Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamide.

Castagna L, Bramanti S, Furst S, Giordano L, Sarina B, Crocchiolo R, El-Cheikh J, Granata A, Morabito L, Mauro E, Faucher C, Mohty B, Harbi S, Devillier R, Chabannon C, Carlo-Stella C, Santoro A, Blaise D.

Bone Marrow Transplant. 2016 Mar;51(3):462-5. doi: 10.1038/bmt.2015.289. Epub 2015 Nov 23. No abstract available. Erratum in: Bone Marrow Transplant. 2016 Mar;51(3):470. Cheikh, J El [corrected to El-Cheikh, J].

PMID:
26595078
47.

T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes.

Devillier R, Bramanti S, Fürst S, Sarina B, El-Cheikh J, Crocchiolo R, Granata A, Chabannon C, Morabito L, Harbi S, Faucher C, Santoro A, Weiller PJ, Vey N, Carlo-Stella C, Castagna L, Blaise D.

Bone Marrow Transplant. 2016 Feb;51(2):194-8. doi: 10.1038/bmt.2015.270. Epub 2015 Nov 9.

PMID:
26551778
48.

Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity.

Garciaz S, Coso D, Schiano de Collela JM, Broussais F, Stoppa AM, Aurran T, Chabannon C, Helvig A, Xerri L, Blaise D, Bouabdallah R.

Bone Marrow Transplant. 2016 Feb;51(2):319-21. doi: 10.1038/bmt.2015.257. Epub 2015 Nov 2. No abstract available.

PMID:
26524266
49.

Comparison of Three Distinct Prophylactic Agents Against Invasive Fungal Infections in Patients Undergoing Haplo-identical Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide.

El-Cheikh J, Crocchiolo R, Vai A, Furst S, Bramanti S, Sarina B, Granata A, Faucher C, Mohty B, Harbi S, Bouabdallah R, Vey N, Santoro A, Chabannon C, Castagna L, Blaise D.

Mediterr J Hematol Infect Dis. 2015 Aug 20;7(1):e2015048. doi: 10.4084/MJHID.2015.048. eCollection 2015.

50.

Haploidentical T Cell-Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen-Matched Related or Unrelated Donor.

Blaise D, Fürst S, Crocchiolo R, El-Cheikh J, Granata A, Harbi S, Bouabdallah R, Devillier R, Bramanti S, Lemarie C, Picard C, Chabannon C, Weiller PJ, Faucher C, Mohty B, Vey N, Castagna L.

Biol Blood Marrow Transplant. 2016 Jan;22(1):119-24. doi: 10.1016/j.bbmt.2015.08.029. Epub 2015 Sep 1.

Supplemental Content

Loading ...
Support Center